Costs and Cost-Effectiveness of New Technologies in Cancer

  • Teresa M. Waters
Part of the Cancer Treatment and Research book series (CTAR, volume 97)


The delivery of healthcare has changed significantly, from the perspective of both physicians and patients, in recent years. Previously, the physician was the advocate of the patient, and the insurer was only a distant, third-party observer who picked up the bill at the end. There were many advantages to this system of care: the patient received high quality care and could be relatively sure that his physician was doing everything possible for him, physicians were free to operate in a relatively independent manner which was professionally satisfying, and America was home to some of the most cutting-edge technologies in the world.


Indirect Cost Cost Analysis Time Preference Direct Medical Cost Relevant Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Secretary of Health and Human Services, Health United States 1995. Washington D.C.: Government Printing Office, 1996.Google Scholar
  2. 2.
    Smith TJ, Hillner B, Neighbors DM, McSorley PA, LeChevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cysplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13(9):2166–73.PubMedGoogle Scholar
  3. 3.
    Bennett CL, Waters TM, Pajeau TS, Pavletic ZS, Tarantolo SR, Bishop MR. Valuing clinical strategies early in development: A cost analysis of allogeneic peripheral blood stem cell transplantation. Ann Int Med, 1998, under review.Google Scholar
  4. 4.
    McKay NL, Phillips KM. An economic evaluation of mandatory premarital testing for HIV. Inquiry 1991; 28:236–248.PubMedGoogle Scholar
  5. 5.
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc 1996; 276(14): 1172–77.CrossRefGoogle Scholar
  6. 6.
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations on cost-effectiveness in health and medicine. J Am Med Assoc 1996; 276(15):1253–58.CrossRefGoogle Scholar
  7. 7.
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. J Am Med Assoc 1996; 276(16): 1339–41.CrossRefGoogle Scholar
  8. 8.
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Google Scholar
  9. 9.
    National Center for Health Statistics. “Reporting of hospitalization in the health interview survey.” In Vital and Health Statistics, Series 2, No. 6, Washington DC: U.S. Government Printing Office, 1965.Google Scholar
  10. 10.
    National Center for Health Statistics. “Health interview responses compared with medical records.” In Vital and Health Statistics, Series 2, No. 7, Washington DC: U.S. Government Printing Office, 1966.Google Scholar
  11. 11.
    National Center for Health Statistics. “Net differences in interview data on chronic conditions and information derived from medical records.” In Vital and Health Statistics, Series 2, No. 57, Washington DC: U.S. Government Printing Office, 1973.Google Scholar
  12. 12.
    Harlow SD, Linet MS. Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol 1989; 129:233PubMedGoogle Scholar
  13. 13.
    Bryant HE, Visser N, Love EJ. Records, recall, loss, and recall bias in pregnancy: a comparison of interview and medical records data of pregnant and postnatal women. Am J Pub Health 1989; 79:78PubMedCrossRefGoogle Scholar
  14. 14.
    Brown JB, Adams ME. Patients as reliable reporters of medical care process: a recall of ambulatory encounter events. Medical Care 1992; 30(5): 400–411.PubMedCrossRefGoogle Scholar
  15. 15.
    Bennett CL, Golub R, Waters TM, Tallman M, Rowe JM. Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible? Cancer Invest 1997; 15(3): 227–235.PubMedGoogle Scholar
  16. 16.
    Lave JR, Pashos CL, Anderson GF, Brailer D, Bubolz T, Conrad D, Freund DA, Fox SH, Keeler E, Lipscomb J, Luft HS, Provenzano G. Costing medical care: Using Medicare administrative data. Medical Care 1994; 32(7): JS77–JS89.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Teresa M. Waters
    • 1
  1. 1.Institute for Health Services Research & Policy StudiesNorthwestern UniversityEvanston

Personalised recommendations